March 8, 2013 07:50 EDT CLDX Celldex price target raised to $16 from $13 at Cantor Cantor increased its price target on Celldex as the firm now expects the company to begin obtaining revenues from both CDX-011 and rindopepimut in 2016 versus its original forecast of 2017. The firm maintains a Buy rating on the stock